{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:33:52Z","timestamp":1790073232203,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:00:00Z","timestamp":1522281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fondecyt","award":["1171213"],"award-info":[{"award-number":["1171213"]}]},{"name":"Fondecyt","award":["11160380"],"award-info":[{"award-number":["11160380"]}]},{"DOI":"10.13039\/501100008736","name":"Fondo de Fomento al Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["ID16i10148"],"award-info":[{"award-number":["ID16i10148"]}],"id":[{"id":"10.13039\/501100008736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008736","name":"Fondo de Fomento al Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["MIII P09\/016-F"],"award-info":[{"award-number":["MIII P09\/016-F"]}],"id":[{"id":"10.13039\/501100008736","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CONICYT-PCHA\/Doctorado Nacional","award":["21130465"],"award-info":[{"award-number":["21130465"]}]},{"name":"FONDECYT POSTDOCTORADO","award":["3170917"],"award-info":[{"award-number":["3170917"]}]},{"name":"CONICYT-PAI\/TESIS DOCTORADO SECTOR PRODUCTIVO","award":["7815110008"],"award-info":[{"award-number":["7815110008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00262-018-2157-5","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T03:27:57Z","timestamp":1522812477000},"page":"1897-1910","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer"],"prefix":"10.1007","volume":"67","author":[{"given":"Daniel","family":"Rojas-Sep\u00falveda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4129-9734","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Tittarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Alejandra","family":"Gleisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"\u00c1valos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristi\u00e1n","family":"Pereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Gallegos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferm\u00edn Eduardo","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes Natalia","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Michel","family":"Butte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Roa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Flux\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1848-5697","authenticated-orcid":false,"given":"Flavio","family":"Salazar-Onfray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,29]]},"reference":[{"issue":"S1","key":"2157_CR1","first-page":"1221","volume":"46","author":"D Rojas-Sep\u00falveda","year":"2016","unstructured":"Rojas-Sep\u00falveda D, Gleisner MA, Pereda C, L\u00f3pez MN, Salazar-Onfray F (2016) Tumor cell lysates as maturation stimulus and antigen source for therapeutic dendritic cells against gallbladder cancer. Eur J Immunol 46(S1):1221\u20131222 (poster)","journal-title":"Eur J Immunol"},{"issue":"1 Supplement","key":"2157_CR2","doi-asserted-by":"crossref","first-page":"79.18","DOI":"10.4049\/jimmunol.198.Supp.79.18","volume":"198","author":"D Rojas-Sep\u00falveda","year":"2017","unstructured":"Rojas-Sep\u00falveda D, Gleisner MA, Pereda C, L\u00f3pez MN, Salazar-Onfray F (2017) Tumor lysate loaded dendritic cells induce a T cell specific antitumor response against gallbladder cancer. J Immunol 198(1 Supplement):79.18 (poster)","journal-title":"J Immunol"},{"key":"2157_CR3","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1517\/14728222.2011.645807","volume":"16 Suppl 2","author":"M Guida","year":"2012","unstructured":"Guida M, Pisconte S, Colucci G (2012) Metastatic melanoma: the new era of targeted therapy. Expert Opin Ther Targets 16 Suppl 2:S61\u2013S70. https:\/\/doi.org\/10.1517\/14728222.2011.645807","journal-title":"Expert Opin Ther Targets"},{"key":"2157_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"2157_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/CMR.0b013e328353e65c","volume":"22","author":"A Farolfi","year":"2012","unstructured":"Farolfi A, Ridolfi L, Guidoboni M, Nicoletti SV, Piciucchi S, Valmorri L et al (2012) Ipilimumab in advanced melanoma: reports of long-lasting responses. Melanoma Res 22:263\u2013270. https:\/\/doi.org\/10.1097\/CMR.0b013e328353e65c","journal-title":"Melanoma Res"},{"key":"2157_CR6","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167\u20133175. https:\/\/doi.org\/10.1200\/JCO.2009.26.7609","journal-title":"J Clin Oncol"},{"key":"2157_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3109\/1547691X.2012.678021","volume":"9","author":"E Simeone","year":"2012","unstructured":"Simeone E, Ascierto PA (2012) Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol 9:241\u2013247. https:\/\/doi.org\/10.3109\/1547691X.2012.678021","journal-title":"J Immunotoxicol"},{"key":"2157_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134\u2013144. https:\/\/doi.org\/10.1056\/NEJMoa1305133","journal-title":"N Engl J Med"},{"issue":"7","key":"2157_CR9","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2217\/imt-2016-0002","volume":"8","author":"C Kyi","year":"2016","unstructured":"Kyi C, Postow MA (2016) Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy 8(7):821\u2013837. https:\/\/doi.org\/10.2217\/imt-2016-0002","journal-title":"Immunotherapy"},{"key":"2157_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1600-065X.2008.00612.x","volume":"222","author":"DM Andrews","year":"2008","unstructured":"Andrews DM, Maraskovsky E, Smyth MJ (2008) Cancer vaccines for established cancer: how to make them better? Immunol Rev 222:242\u2013255. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00612.x","journal-title":"Immunol Rev"},{"issue":"6","key":"2157_CR11","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.2008.18.0794","volume":"27","author":"MN L\u00f3pez","year":"2009","unstructured":"L\u00f3pez MN, Pereda C, Segal G, Mu\u00f1oz L, Aguilera R, Gonz\u00e1lez FE et al (2009) Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 27(6):945\u2013952. https:\/\/doi.org\/10.1200\/JCO.2008.18.0794","journal-title":"J Clin Oncol"},{"issue":"11","key":"2157_CR12","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.4161\/21645515.2014.982996","volume":"10","author":"FE Gonz\u00e1lez","year":"2014","unstructured":"Gonz\u00e1lez FE, Gleisner A, Falc\u00f3n-Beas F, Osorio F, L\u00f3pez MN, Salazar-Onfray F (2014) Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccin Immunother 10(11):3261\u20133269. https:\/\/doi.org\/10.4161\/21645515.2014.982996","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"2157_CR13","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/1078-0432.CCR-10-2384","volume":"17","author":"R Aguilera","year":"2011","unstructured":"Aguilera R, Saffie C, Tittarelli A, Gonz\u00e1lez FE, Ram\u00edrez M, Reyes D et al (2011) Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res 17(8):2474\u20132483. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2384","journal-title":"Clin Cancer Res"},{"key":"2157_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/CLEP.S37357","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA (2014) Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 6:99\u2013109. https:\/\/doi.org\/10.2147\/CLEP.S37357","journal-title":"Clin Epidemiol"},{"issue":"5","key":"2157_CR15","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u2013E386. https:\/\/doi.org\/10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"issue":"5","key":"2157_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1309\/AJCPQT3ELN2BBCKA","volume":"141","author":"I Roa","year":"2014","unstructured":"Roa I, Ibacache G, Mu\u00f1oz S, de Aretxabala X (2014) Gallbladder cancer in Chile: pathologic characteristics of survival and prognostic factors: analysis of 1,366 cases. Am J Clin Pathol 141(5):675\u2013682. https:\/\/doi.org\/10.1309\/AJCPQT3ELN2BBCKA","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2157_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/MOG.0000000000000164","volume":"31","author":"I Roa","year":"2015","unstructured":"Roa I, de Aretxabala X (2015) Gallbladder cancer in Chile: what have we learned? Curr Opin Gastroenterol 31(3):269\u2013275. https:\/\/doi.org\/10.1097\/MOG.0000000000000164","journal-title":"Curr Opin Gastroenterol"},{"issue":"10","key":"2157_CR18","first-page":"954","volume":"114","author":"G Smok","year":"1986","unstructured":"Smok G, Cervilla K, Bosch H, Csendes A (1986) Precancerous lesions of invasive carcinoma of the gallbladder. Rev Med Chil 114(10):954\u2013958","journal-title":"Rev Med Chil"},{"issue":"6","key":"2157_CR19","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/j.1572-0241.2000.02070.x","volume":"95","author":"S Sheth","year":"2000","unstructured":"Sheth S, Bedford A, Chopra S (2000) Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol 95(6):1402\u20131410. https:\/\/doi.org\/10.1111\/j.1572-0241.2000.02070.x","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2157_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1365-2249.2005.02948.x","volume":"142","author":"A Escobar","year":"2005","unstructured":"Escobar A, L\u00f3pez M, Serrano A, Ramirez M, P\u00e9rez C, Aguirre A, Gonz\u00e1lez R, Alfaro J, Larrondo M, Fodor M, Ferrada C, Salazar-Onfray F (2005) Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 142(3):555\u2013568. https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02948.x","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"2157_CR21","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3748\/wjg.v22.i4.1335","volume":"22","author":"EI Marks","year":"2016","unstructured":"Marks EI, Yee NS (2016) Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol 22(4):1335\u20131347. https:\/\/doi.org\/10.3748\/wjg.v22.i4.1335","journal-title":"World J Gastroenterol"},{"issue":"10","key":"2157_CR22","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1038\/bjc.2013.610","volume":"109","author":"B Goeppert","year":"2013","unstructured":"Goeppert B, Frauenschuh L, Zucknick M, Stenzinger A, Andrulis M, Klauschen F et al (2013) Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer 109(10):2665\u20132674. https:\/\/doi.org\/10.1038\/bjc.2013.610","journal-title":"Br J Cancer"},{"issue":"9","key":"2157_CR23","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/sj.bjc.6601331","volume":"89","author":"Y Nakakubo","year":"2003","unstructured":"Nakakubo Y, Miyamoto M, Cho Y, Hida Y, Oshikiri T, Suzuoki M, Hiraoka K, Itoh T, Kondo S, Katoh H (2003) Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 89(9):1736\u20131742. https:\/\/doi.org\/10.1038\/sj.bjc.6601331","journal-title":"Br J Cancer"},{"issue":"1","key":"2157_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12885-018-4147-6","volume":"18","author":"P Flux\u00e1","year":"2018","unstructured":"Flux\u00e1 P, Rojas-Sep\u00falveda D, Gleisner MA, Tittarelli A, Villegas P, Tapia L et al (2018) High CD8(+) and absence of Foxp3(+) T lymphocytes infiltration in gallbladder tumors correlate with prolonged patients survival. BMC Cancer 18(1):243. https:\/\/doi.org\/10.1186\/s12885-018-4147-6","journal-title":"BMC Cancer"},{"issue":"12","key":"2157_CR25","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/cas.12825","volume":"106","author":"S Oguro","year":"2015","unstructured":"Oguro S, Ino Y, Shimada K, Hatanaka Y, Matsuno Y, Esaki M et al (2015) Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer. Cancer Sci 106(12):1750\u20131760. https:\/\/doi.org\/10.1111\/cas.12825","journal-title":"Cancer Sci"},{"issue":"12","key":"2157_CR26","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1158\/1078-0432.CCR-11-2417","volume":"18","author":"HJ Lee","year":"2012","unstructured":"Lee HJ, Lee K, Lee DG, Bae KH, Kim JS, Liang ZL et al (2012) Chemokine (C-X-C motif) ligand 12 is associated with gallbladder carcinoma progression and is a novel independent poor prognostic factor. Clin Cancer Res 18(12):3270\u20133280. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2417","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2157_CR27","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ijc.30134","volume":"139","author":"RS Patil","year":"2016","unstructured":"Patil RS, Shah SU, Shrikhande SV, Goel M, Dikshit RP, Chiplunkar SV (2016) IL17 producing \u03b3\u03b4T cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int J Cancer 139(4):869\u2013881. https:\/\/doi.org\/10.1002\/ijc.30134","journal-title":"Int J Cancer"},{"issue":"3","key":"2157_CR28","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1007\/s13277-015-4743-x","volume":"37","author":"Y Chai","year":"2016","unstructured":"Chai Y (2016) Immunotherapy of biliary tract cancer. Tumour Biol 37(3):2817\u20132821. https:\/\/doi.org\/10.1007\/s13277-015-4743-x","journal-title":"Tumour Biol"},{"issue":"2","key":"2157_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00534-011-0437-y","volume":"19","author":"K Shimizu","year":"2012","unstructured":"Shimizu K, Kotera Y, Aruga A, Takeshita N, Takasaki K, Yamamoto M (2012) Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 19(2):171\u2013178. https:\/\/doi.org\/10.1007\/s00534-011-0437-y","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"2","key":"2157_CR30","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/vaccines3020344","volume":"3","author":"CL Chiang","year":"2015","unstructured":"Chiang CL, Coukos G, Kandalaft LE (2015) Whole tumor antigen vaccines: where are we? Vaccines (Basel) 3(2):344\u2013372. https:\/\/doi.org\/10.3390\/vaccines3020344","journal-title":"Vaccines (Basel)"},{"key":"2157_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00663","author":"L Vandenberk","year":"2016","unstructured":"Vandenberk L, Belmans J, Van Woensel M, Riva M, Van Gool SW (2016) Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2015.00663","journal-title":"Front Immunol"},{"issue":"6236","key":"2157_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA et al (2015) Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348(6236):803\u2013808. https:\/\/doi.org\/10.1126\/science.aaa3828","journal-title":"Science"},{"issue":"7662","key":"2157_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ et al (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547(7662):217\u2013221. https:\/\/doi.org\/10.1038\/nature22991","journal-title":"Nature"},{"issue":"6184","key":"2157_CR34","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Parkhurst MR (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344(6184):641\u2013645. https:\/\/doi.org\/10.1126\/science.1251102","journal-title":"Science"},{"issue":"23","key":"2157_CR35","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1200\/JCO.2002.01.151","volume":"20","author":"EC Hsueh","year":"2002","unstructured":"Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O\u2019Day SJ, Boasberg PD, Stern SL, Ye X, Morton DL (2002) Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20(23):4549\u20134554. https:\/\/doi.org\/10.1200\/JCO.2002.01.151","journal-title":"J Clin Oncol"},{"issue":"4","key":"2157_CR36","first-page":"421","volume":"57","author":"J Mordoh","year":"1997","unstructured":"Mordoh J, Kairiyama C, Bover L, Solarolo E (1997) Allogeneic cells vaccine increases disease-free survival in stage III melanoma patients. A non randomized phase II study. Medicina (Buenos Aires) 57(4):421\u2013427","journal-title":"Medicina (Buenos Aires)"},{"issue":"5","key":"2157_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10434-001-0389-6","volume":"8","author":"N Habal","year":"2001","unstructured":"Habal N, Gupta RK, Bilchik AJ, Yee R, Leopoldo Z, Ye W, Elashoff RM, Morton DL (2001) CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 8(5):389\u2013401","journal-title":"Ann Surg Oncol"},{"issue":"17","key":"2157_CR38","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1016\/S0264-410X(00)00490-4","volume":"19","author":"D Berd","year":"2001","unstructured":"Berd D (2001) Autologous, hapten-modified vaccine as a treatment for human cancers. Vaccine 19(17):2565\u20132570. https:\/\/doi.org\/10.1016\/S0264-410X(00)00490-4","journal-title":"Vaccine"},{"issue":"35","key":"2157_CR39","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1200\/JCO.2009.23.3494","volume":"27","author":"LA Emens","year":"2009","unstructured":"Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Stearns V (2009) Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte\u2013macrophage colony-stimulating factor\u2014secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27(35):5911\u20135918. https:\/\/doi.org\/10.1200\/JCO.2009.23.3494","journal-title":"J Clin Oncol"},{"issue":"6","key":"2157_CR40","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/sj.cgt.7700922","volume":"13","author":"J Nemunaitis","year":"2006","unstructured":"Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B, Jablons D, Aimi J, Lin A, Hege K (2006) Phase 1\/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 13(6):555\u2013562. https:\/\/doi.org\/10.1038\/sj.cgt.7700922","journal-title":"Cancer Gene Ther"},{"issue":"13","key":"2157_CR41","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1158\/1078-0432.CCR-06-2937","volume":"13","author":"EJ Small","year":"2007","unstructured":"Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS et al (2007) Granulocyte macrophage colony-stimulating factor\u2014secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13(13):3883\u20133891. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2937","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2157_CR42","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/01.cji.0000208258.79005.5f","volume":"29","author":"MM Barrio","year":"2006","unstructured":"Barrio MM, de Motta PT, Kaplan J, von Euw EM, Bravo AI, Chac\u00f3n RD, Mordoh J (2006) A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J Immunother 29(4):444\u2013454. https:\/\/doi.org\/10.1097\/01.cji.0000208258.79005.5f","journal-title":"J Immunother"},{"issue":"4","key":"2157_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/gt.2010.143","volume":"18","author":"J Westermann","year":"2011","unstructured":"Westermann J, Fl\u00f6rcken A, Willimsky G, van Lessen A, Kopp J, Takvorian A et al (2011) Allogeneic gene-modified tumor cells (RCC-26\/IL-7\/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. Gene Ther 18(4):354\u2013363. https:\/\/doi.org\/10.1038\/gt.2010.143","journal-title":"Gene Ther"},{"issue":"2","key":"2157_CR44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.lungcan.2006.01.007","volume":"52","author":"A Powell","year":"2006","unstructured":"Powell A, Creaney J, Broomfield S, Van Bruggen I, Robinson B (2006) Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer 52(2):189\u2013197. https:\/\/doi.org\/10.1016\/j.lungcan.2006.01.007","journal-title":"Lung Cancer"},{"issue":"6","key":"2157_CR45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.semcancer.2003.09.004","volume":"13","author":"VK Sondak","year":"2003","unstructured":"Sondak VK, Sosman JA (2003) Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine. Semin Cancer Biol 13(6):409\u2013415. https:\/\/doi.org\/10.1016\/j.semcancer.2003.09.004","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"2157_CR46","first-page":"1021","volume":"8","author":"AE Chang","year":"2002","unstructured":"Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Mul\u00e9 JJ (2002) A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8(4):1021\u20131032","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2157_CR47","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.1158\/1078-0432.CCR-13-1185","volume":"19","author":"CL Chiang","year":"2013","unstructured":"Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N et al (2013) A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 19(17):4801\u20134815. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1185","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2157_CR48","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/bjc.2015.337","volume":"113","author":"B Goeppert","year":"2015","unstructured":"Goeppert B, Frauenschuh L, Zucknick M, Roessler S, Mehrabi A, Hafezi M, Stenzinger A, Warth A, Pathil A, Renner M, Schirmacher P, Weichert W (2015) Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. Br J Cancer 113(9):1343\u20131349. https:\/\/doi.org\/10.1038\/bjc.2015.337","journal-title":"Br J Cancer"},{"key":"2157_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","volume":"39","author":"F Garrido","year":"2016","unstructured":"Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T (2016) The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 39:44\u201351. https:\/\/doi.org\/10.1016\/j.coi.2015.12.007","journal-title":"Curr Opin Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2157-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2157-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2157-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T22:35:40Z","timestamp":1693607740000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2157-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,29]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2157"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2157-5","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,29]]},"assertion":[{"value":"1 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The use of paraffin embedded GBC tissue of the patients was approved by the bioethical committee of the Hospital Cl\u00ednico of the Universidad de Chile (Approval act 75), which authorize the use of biopsies under the supervision of the director of the Pathological Anatomy Service (Dr. Iv\u00e1n Gallegos). Informed consent from patients was not required for this work, given that it corresponds to a retrospective study. The Bioethical Committee of the Centro Metropolitano de Sangre y Tejidos, Hospital Metropolitano (Santiago de Chile) approved the use of buffy coats from healthy donors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}}]}}